ClinicalTrials.gg
Active, not recruitingNCT06458413Updated Oct 16, 2026

Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer

A Phase 2 interventional study of Utidelone Capsule Plus Capecitabine in Breast Cancer Recurrent, sponsored by Min Yan, MD. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Min Yan, MD · Phase 2, Interventional, and Treatment

How we know

Updated Oct 16, 2026Now Active, not recruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies testing desoxyepothilone B in Breast Neoplasms — 8 open to participants now, 9 under way, 4 of them phase 3. desoxyepothilone B · Breast Neoplasms.

Planned enrollment
12th of 14
40 · median 110
Started
2024
with 2 others
Phase 2
7 of 14
4 open now
Registered
10th of 14
by date
Lead sponsor
1 of 14
Min Yan, MD

Among the 14 studies testing desoxyepothilone B in Breast Neoplasms, this one is the 12th largest by planned enrollment, is one of 3 that started in 2024, is one of 7 in phase 2, and was the 10th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 14 studies testing desoxyepothilone B in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About desoxyepothilone B

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing desoxyepothilone B in Breast Neoplasms, or all of them as a file.
02

Study summary

This study aims to investigate the efficacy and safety of utidelone capsule plus Capecitabine in the treatment of advanced breast cancer , and thus provides a new systemic treatment strategy for those patients.

This study was a single-arm, phase II study of patients with recurrent or metastatic HER2-negative breast cancer who had previously received chemotherapy regimens containing taxanes and/or anthracyclines were treated with a combination of utidelone capsules and capecitabine. The main objective was to explore the efficacy and safety of the combined regimen.

Read the detailed description

Patients with recurrent or metastatic HER2 negative breast cancer who have previously received chemotherapy containing taxanes and/or anthracyclines will receive combined treatment with utidelone capsule and capecitabine. Utidelone Capsule: 60mg/m2/d, once daily, oral on an empty stomach, continuously administered for 1-5 days; Capecitabine tablets: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals, and continuously administered for 14 days from day 1 to day 14. Every 21 days is a cycle until disease progression, intolerable adverse events occur, subjects voluntarily withdraw, or the researcher determines that medication must be terminated.

03

Conditions studied

  • Breast Cancer Recurrent

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in this study, sign an form, have good compliance, and are willing to follow-up.
  2. Female, aged ≥ 18 and ≤ 70 years, with an score of 0-1 and an expected survival time of ≥ 12 weeks.
  3. The pathological and/or cytological diagnosis (based on the latest results) is negative recurrent or breast cancer, regardless of hormone receptor status (ER/PR positive or negative, but the hormone receptor status needs to be determined);
  4. All patients have received at least paclitaxel and/or anthracycline as a treatment option;
  5. All patients with prior treatment ≤ 3 lines (for those who progress during the /adjuvant period or within 12 months after the end of the last treatment, it is considered as the , and no progress is counted as the number of lines); For HR+/HER2- breast cancer patients, they also need to have received the first line systemic CDK4/6 inhibitor+endocrine therapy before the disease progresses.
  6. According to 1.1 standard, there is at least one measurable extracranial lesion present.
  7. Within one week before enrollment, the blood routine examination was basically normal (no blood transfusion within two weeks, no use of drugs to increase white blood cells or ):

    (ANC) ≥ 1.5 × 109/L; Platelet count (PLT) ≥ 90 × 109/L; ≥ 9.0 g/dL.

  8. Within one week before enrollment, the blood biochemistry test was basically normal (based on the normal values of each research center laboratory): Total (TBIL) ≤ 1.5 x value (ULN) /ALT ≤ 3 × ULN (liver metastasis patients ≤ 5 × ULN); SGOT/AST ≤ 3 × ULN (liver metastasis patients ≤ 5 × ULN); The rate (Ccr) is ≥ 50 ml/min (Cockcroft Gault formula).
  9. Adequate coagulation function: defined as (INR) or prothrombin time (PT) ≤1.5 × ULN. If the subject is receiving anticoagulant therapy, PT is acceptable as long as it is within the target range specified for the anticoagulant.
  10. No major organ dysfunction
  11. Women with fertility must agree to use effective methods during the study period and within 6 months after the last study medication. Women with fertility must have a negative blood or urine pregnancy test before enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Other malignant tumors within the 5 years prior to enrollment, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, papillary thyroid carcinoma without lymph node , or squamous cell carcinoma of the skin.
  2. Those who meet the following conditions:

    1. Received systemic anti-tumor therapy within 2 weeks prior to enrollment, including but not limited to endocrine therapy, small molecule targeted therapy, anti-tumor traditional Chinese medicine, etc;
    2. Within the 4 weeks prior to enrollment, chemotherapy, targeted biological therapy or immunotherapy, other clinical drugs, radiation therapy, or major organ surgery (excluding ) or significant trauma have been received, or elective surgery is required during the trial period. Those who have undergone major surgeries;
    3. Received nitroso urea or mitomycin C within 6 weeks prior to enrollment;
  3. Individuals who have previously received treatment with Utidelone injection.
  4. Peripheral neuropathy 5.0 grade evaluation ≥ 2.
  5. Those who have received treatment with capecitabine or other drugs with an active ingredient of 5-fluorouracil (excluding those who received /adjuvant therapy and relapse after more than 12 months of treatment).
  6. Pregnant and lactating patients.
  7. Adverse reactions from previous anti-tumor treatments have not yet recovered to CTCAE 5.0 grade ≤1 (excluding toxicity judged by researchers to have no safety risk for hair loss).
  8. Accompanied by meningeal metastasis; Accompanied by uncontrollable (researchers have determined that new asymptomatic brain metastases or those known to have stable brain metastases after treatment can be enrolled); Or uncontrollable bone metastasis, which refers to patients who have or have recently been at risk of fractures or have obvious symptoms or other critical situations.
  9. Uncontrollable pleural effusion, pericardial effusion, or abdominal effusion.
  10. Individuals with active infections who currently require systematic anti infection treatment.
  11. Have a history of immunodeficiency, including antibody testing positive, or have other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation.
  12. Individuals with active or ; Known active syphilis infection.
  13. Have a history of severe cardiovascular and cerebrovascular diseases, including but not limited to:

    Serious cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, grade II-III atrioventricular block, etc; At rest, the average obtained from three 12 lead examinations is>470ms; Acute coronary syndrome, congestive heart failure or systolic dysfunction (\<50%), aortic dissection, stroke, or other Grade 3 or higher cardiovascular events occurring within 6 months prior to the first administration; Hypertension that cannot be controlled clinically. Other researchers have identified high-risk heart diseases.

  14. Uncontrolled diabetes patients.
  15. Patients with active gastrointestinal ulcers.
  16. Have a clear history of neurological or psychiatric disorders, including epilepsy or dementia.
  17. Participate in another clinical trial or use other investigational treatments simultaneously.
  18. Individuals known to be allergic to the investigational drug or any of its .
  19. The researchers believe that the subjects have a history of other serious systemic diseases or other reasons that make them unsuitable to participate in this trial.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Single-arm

    Patients with HER2-negative breast cancer were treated with Utidelone Capsule combined with Capecitabine tablets.

    Drug: Utidelone Capsule Plus Capecitabine

Interventions

  • DrugUtidelone Capsule Plus Capecitabine

    Drug pages: Desoxyepothilone BStudies of Desoxyepothilone BDesoxyepothilone B pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CapecitabineStudies of CapecitabineCapecitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Utidelone Capsule: 60mg/m2/d, once daily, oral on an empty stomach, continuously administered for 1-5 days; Capecitabine tablets: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals, and continuously administered for 14 days from day 1 to day 14. Every 21 days is a cycle .

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants in the analysis population who have CR or PR per RECIST 1.1.

    Time frame: 18 months

Secondary outcomes

  1. Progression-Free Survival(PFS)

    time from the first dose to disease progression or any-cause death

    Time frame: 18 months

  2. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants in the analysis population who have CR or PR or SD per RECIST 1.1.

    Time frame: 18 months

  3. Duration of response (DoR)

    DOR is defined as the interval from response initiation (when either CR or PR is first determined) to progression or death, whichever occurs first.

    Time frame: 18 months

  4. Overall survival (OS)

    time from the first dose of study drug to any-cause death

    Time frame: 18 months

  5. Treatment-related Adverse Event-TRAE

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: Until 28 days after the last dose of treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after de-identification are available following article publication.

Supporting information: Study protocol

Time frame: Three years from publication

Access criteria: Please contact Central contact person by Email

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jul 2026, 25 months.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 25 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jun 2025 → Jul 2026 and completion Dec 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 13, 2024
StartActual
Jun 6, 2024
Primary completionActual
Jul 9, 2026was Jun 2025
CompletionEst.
Dec 30, 2026was Dec 2025
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 16, 2026
Start date
Jun 5, 2024→Jun 6, 2024
Oct 16, 2026
Primary completion
Jun 5, 2025→Jul 9, 2026 (actual)
Oct 16, 2026
Study completion
Dec 5, 2025→Dec 30, 2026
Oct 16, 2026
Eligibility
1 inclusion criterion added; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • AddedAdequate coagulation function: defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN. If the subject is receiving anticoagulant therapy, PT is acceptable as long as it is within the target range specified for the anticoagulant.
Exclusion criteria
  • EditedThose who have received treatment with capecitabine or other drugs with an active ingredient of 5-fluorouracil (excluding those who received neoadjuvant/adjuvant therapy and relapse after more than 12 months of treatment).
  • EditedSerious cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, grade II-III atrioventricular block, etc; At rest, the average QTcF obtained from three 12 lead electrocardiogram examinations is>470ms; Acute coronary syndrome, congestive heart failure or systolic dysfunction (LVEF<50%), aortic dissection, stroke, or other Grade 3 or higher cardiovascular events occurring within 6 months prior to the first administration; Hypertension that cannot be controlled clinically. Other researchers have identified high-risk heart diseases.
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Active, not recruiting
    Start date Jun 5, 2024→Jun 6, 2024
    Primary completion Jun 5, 2025→Jul 9, 2026 (now actual)
    Study completion Dec 5, 2025→Dec 30, 2026
    Eligibility 1 inclusion criterion added; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • AddedAdequate coagulation function: defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN. If the subject is receiving anticoagulant therapy, PT is acceptable as long as it is within the target range specified for the anticoagulant.
    Exclusion criteria
    • EditedThose who have received treatment with capecitabine or other drugs with an active ingredient of 5-fluorouracil (excluding those who received neoadjuvant/adjuvant therapy and relapse after more than 12 months of treatment).
    • EditedSerious cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, grade II-III atrioventricular block, etc; At rest, the average QTcF obtained from three 12 lead electrocardiogram examinations is>470ms; Acute coronary syndrome, congestive heart failure or systolic dysfunction (LVEF<50%), aortic dissection, stroke, or other Grade 3 or higher cardiovascular events occurring within 6 months prior to the first administration; Hypertension that cannot be controlled clinically. Other researchers have identified high-risk heart diseases.
    + 5 other changes: identifiers, verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06458413
Lead sponsor
Min Yan, MD
Collaborators
Beijing Biostar Pharmaceuticals Co., Ltd.
Responsible party
Min Yan, MD (Professor, Henan Cancer Hospital) — Sponsor-investigator
First posted
Jun 13, 2024
Start date
Jun 6, 2024
Primary completion
Jul 9, 2026
Completion
Dec 30, 2026 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Desoxyepothilone B · Capecitabine

Start the discussion